[go: up one dir, main page]

WO2005115389A3 - Nouvelle utilisation - Google Patents

Nouvelle utilisation Download PDF

Info

Publication number
WO2005115389A3
WO2005115389A3 PCT/IB2005/001438 IB2005001438W WO2005115389A3 WO 2005115389 A3 WO2005115389 A3 WO 2005115389A3 IB 2005001438 W IB2005001438 W IB 2005001438W WO 2005115389 A3 WO2005115389 A3 WO 2005115389A3
Authority
WO
WIPO (PCT)
Prior art keywords
energy balance
negative energy
compound
ruminants
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001438
Other languages
English (en)
Other versions
WO2005115389A2 (fr
Inventor
Marcus Eugene Kehrli Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0511481-0A priority Critical patent/BRPI0511481A/pt
Priority to CA002567398A priority patent/CA2567398A1/fr
Priority to EP05738586A priority patent/EP1753426A2/fr
Priority to JP2007514167A priority patent/JP2008500323A/ja
Priority to AU2005247164A priority patent/AU2005247164B2/en
Priority to MXPA06013754A priority patent/MXPA06013754A/es
Priority to US11/569,513 priority patent/US20070281935A1/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2005115389A2 publication Critical patent/WO2005115389A2/fr
Priority to NO20065038A priority patent/NO20065038L/no
Priority to IL179244A priority patent/IL179244A0/en
Publication of WO2005115389A3 publication Critical patent/WO2005115389A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de formule I, d'un isomère de ce dernier, d'un promédicament dudit composé ou isomère ou d'un sel pharmaceutiquement acceptable dudit composé, isomère ou promédicament dans la production d'un médicament pour le traitement palliatif, prophylactique ou curatif d'un bilan énergétique négatif chez les ruminants. Cette invention concerne également l'utilisation d'un composé de formule I dans la production d'un médicament pour le traitement palliatif, prophylactique ou curatif d'une maladie de ruminants associée à un bilan énergétique négatif chez les ruminants, cette maladie des ruminants associée à un bilan énergétique négatif chez les ruminants étant, de préférence, sélectionnée parmi le syndrome du foie gras, la dystocie, un dysfonctionnement immunitaire, une déficience de la fonction immunitaire, la contamination toxique, la cétose primaire, la cétose secondaire, le syndrome de la vache à terre, l'indigestion, l'anorexie, la rétention du placenta, le déplacement de la caillette, la mastite, la métrite, l'endométrite, la stérilité, la faible fertilité et la boiterie.
PCT/IB2005/001438 2004-05-25 2005-05-13 Nouvelle utilisation Ceased WO2005115389A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002567398A CA2567398A1 (fr) 2004-05-25 2005-05-13 Nouvelle utilisation
EP05738586A EP1753426A2 (fr) 2004-05-25 2005-05-13 Nouvelle utilisation
JP2007514167A JP2008500323A (ja) 2004-05-25 2005-05-13 新規用途
AU2005247164A AU2005247164B2 (en) 2004-05-25 2005-05-13 Specific PPAR agonists for treating negative energy balance
MXPA06013754A MXPA06013754A (es) 2004-05-25 2005-05-13 Uso novedoso.
BRPI0511481-0A BRPI0511481A (pt) 2004-05-25 2005-05-13 uso
US11/569,513 US20070281935A1 (en) 2004-05-25 2005-05-13 Use
NO20065038A NO20065038L (no) 2004-05-25 2006-11-02 Anvendelse.
IL179244A IL179244A0 (en) 2004-05-25 2006-11-13 Specific ppar agonists for treating negative energy balance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57417104P 2004-05-25 2004-05-25
US60/574,171 2004-05-25

Publications (2)

Publication Number Publication Date
WO2005115389A2 WO2005115389A2 (fr) 2005-12-08
WO2005115389A3 true WO2005115389A3 (fr) 2006-11-16

Family

ID=34967765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001438 Ceased WO2005115389A2 (fr) 2004-05-25 2005-05-13 Nouvelle utilisation

Country Status (15)

Country Link
US (1) US20070281935A1 (fr)
EP (1) EP1753426A2 (fr)
JP (1) JP2008500323A (fr)
CN (1) CN1956719A (fr)
AR (1) AR049185A1 (fr)
AU (1) AU2005247164B2 (fr)
BR (1) BRPI0511481A (fr)
CA (1) CA2567398A1 (fr)
IL (1) IL179244A0 (fr)
MX (1) MXPA06013754A (fr)
NO (1) NO20065038L (fr)
RU (1) RU2353362C2 (fr)
TW (1) TWI280879B (fr)
WO (1) WO2005115389A2 (fr)
ZA (1) ZA200609235B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500328A (ja) * 2004-05-25 2008-01-10 ファイザー・プロダクツ・インク 新規な使用
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
JP2010511038A (ja) * 2006-12-01 2010-04-08 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体阻害剤としての３−ヘテロアリール（アミノ又はアミド）−１−（ビフェニル又はフェニルチアゾリル）カルボニルピペリジン誘導体
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
EP2137150A1 (fr) * 2007-03-12 2009-12-30 Biolipox AB Pipéridinones utiles dans le traitement d'une inflammation
CN104762224B (zh) * 2008-12-02 2019-05-28 杜邦营养生物科学有限公司 用于改善反刍动物健康和/或性能的菌株和方法
DE102009038123A1 (de) 2009-08-17 2011-02-24 Aicuris Gmbh & Co. Kg Substituierte (Thiazolyl-carbonyl)imidazolidinone und ihre Verwendung
WO2011114103A1 (fr) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones pour usage médicamenteux
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
CN116162056A (zh) * 2021-11-24 2023-05-26 上海医药工业研究院 β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用
WO2024145931A1 (fr) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 INHIBITEUR À PETITES MOLÉCULES POUR L'INTERACTION PROTÉINE-PROTÉINE β-CATÉNINE/BCL9 ET UTILISATION ASSOCIÉE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259337A (en) * 1976-02-13 1981-03-31 Roussel Uclaf Method for using m-trifluoromethylphenyl-piperidines
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2004048334A1 (fr) * 2002-11-26 2004-06-10 Pfizer Products Inc. Composes de piperidine phenyle a substitution phenyle s'utilisant comme activateurs de ppar
WO2004096139A2 (fr) * 2003-04-24 2004-11-11 Incyte Corporation Derives d'aza spiro alcane en tant qu'inhibiteurs de metalloproteases
WO2005115369A2 (fr) * 2004-05-25 2005-12-08 Pfizer Products Inc. Nouvelle utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221092B1 (en) * 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259337A (en) * 1976-02-13 1981-03-31 Roussel Uclaf Method for using m-trifluoromethylphenyl-piperidines
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2004048334A1 (fr) * 2002-11-26 2004-06-10 Pfizer Products Inc. Composes de piperidine phenyle a substitution phenyle s'utilisant comme activateurs de ppar
WO2004096139A2 (fr) * 2003-04-24 2004-11-11 Incyte Corporation Derives d'aza spiro alcane en tant qu'inhibiteurs de metalloproteases
WO2005115369A2 (fr) * 2004-05-25 2005-12-08 Pfizer Products Inc. Nouvelle utilisation

Also Published As

Publication number Publication date
IL179244A0 (en) 2007-03-08
RU2353362C2 (ru) 2009-04-27
MXPA06013754A (es) 2007-02-08
BRPI0511481A (pt) 2007-12-26
TWI280879B (en) 2007-05-11
ZA200609235B (en) 2008-08-27
TW200607501A (en) 2006-03-01
AR049185A1 (es) 2006-07-05
AU2005247164A1 (en) 2005-12-08
EP1753426A2 (fr) 2007-02-21
CN1956719A (zh) 2007-05-02
AU2005247164B2 (en) 2008-11-27
US20070281935A1 (en) 2007-12-06
CA2567398A1 (fr) 2005-12-08
RU2006141628A (ru) 2008-05-27
WO2005115389A2 (fr) 2005-12-08
NO20065038L (no) 2006-12-01
JP2008500323A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2005115389A3 (fr) Nouvelle utilisation
Luo et al. Partial or total replacement of fishmeal by solvent‐extracted cottonseed meal in diets for juvenile rainbow trout (Oncorhynchus mykiss)
Rodrigues A review on the effects of mycotoxins in dairy ruminants
ES2196556T3 (es) Formulacion en granulos para el tratamiento del tracto intestinal.
Zhao et al. Effects of feeding frequency and dietary protein levels on juvenile allogynogenetic gibel carp (C arassius auratus gibelio) var. CAS III: growth, feed utilization and serum free essential amino acids dynamics
WO2004060345A3 (fr) Compositions pharmaceutiques dispersibles
Langendijk et al. Effects of boar contact and housing conditions on estrus expression in weaned sows
NO325884B1 (no) Enkel farmasoytisk doseringsform med COX-2-inhibitor og oksykodon eller morfin, og anvendelse av COX-2-inhibitor, oksykodon eller morfin, for fremstilling av den samme.
WO2005115369A3 (fr) Nouvelle utilisation
Orgeur et al. The influence of rearing conditions on the social relationships of young male goats (Capra hircus)
TW200631579A (en) Drugs and prodrugs useful for the treatment of energy balance in ruminants
WO2024073752A3 (fr) Schémas posologiques de rispéridone avec systèmes de résidence gastrique
US5331003A (en) Anticoccidial methods
WO2005092068A3 (fr) Nouveau procede de neuroprotection par inhibition pharmacologique de la kinase de proteine activee par amp
Yadav et al. Haemato-biochemical and therapeutic evaluation of doxorubicin and vincristine in canine transmissible venereal tumour
Brown et al. Postweaning performance of calves from Angus, Brahman, and reciprocal-cross cows grazing endophyte-infected tall fescue or common bermudagrass
Hendel et al. PSII-22 trends in mycotoxin contamination in United States Corn
Perry Effects of peri-AI nutritional management on embryo development and pregnancy success
Lamglait et al. Patent ductus arteriosus in a greater kudu (Tragelaphus strepsiceros)
WO2011093612A3 (fr) Composition complexe orale comprenant la pseudoéphédrine et la lévocétirizine
Naserian et al. Milk production and components of Holstein dairy cows fed diet supplemented with whole barley grain treated with sodium hydroxide
Naeemipour et al. Quantile regression mixed model at different milk production levels of Iranian Holsteins
Jenkins et al. 11 The effect of increased standardized ileal digestible lysine through increased soybean meal during late gestation on lactating sow and litter performance
Petrone et al. Effects of Dietary Omega-3 Fatty Acids on Growth and Reproduction in Gilts Farrowed By Sows Fed Diets Rich in Omega-3 Fatty Acids
García-Ruiz et al. Effect of yeast β-glucans on rabbit performances and mortality from 35 to 63 days of age

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200609235

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 551173

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 179244

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12006502290

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2005738586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2567398

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067024630

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013754

Country of ref document: MX

Ref document number: 06119249

Country of ref document: CO

Ref document number: 2006141628

Country of ref document: RU

Ref document number: 200580016770.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007514167

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005247164

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 7465/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005247164

Country of ref document: AU

Date of ref document: 20050513

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005247164

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005738586

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067024630

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11569513

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11569513

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0511481

Country of ref document: BR